ALBENMED
Live / Registered — Registered (as of 14 Jan 2025)
What this means for you
Registered since 14 Jan 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98402369
- Registration number
- 7650980
- Mark type
- Stylized text
- Filed
- 12 Feb 2024
- Published for opposition
- 26 Nov 2024
- Registered
- 14 Jan 2025
- Attorney of record
- Ashley D. Johnson
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical compositions and medicaments for use in treatment of cancer; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, inhibiting the proliferation, metastasis and angiogenic activity of malignant cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, regulation of one or more kinase signaling pathway, reversing multi-drug resistance, inhibiting tumor stem cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, providing anti-inflammatory and antiviral properties; Pharmaceutical compositions and medicaments for use in the treatment of cancer
Owner
- Right2Try Inc., Lewes, DE, US
- Right2Try Inc., Lewes, DE, US
- Right2Try Inc., Lewes, DE, US
Prosecution history
- 14 Jan 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 14 Jan 2025 — REGISTERED-PRINCIPAL REGISTER
- 26 Nov 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Nov 2024 — PUBLISHED FOR OPPOSITION
- 20 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 Oct 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Sept 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 20 Sept 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 20 Sept 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 20 Sept 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 20 Sept 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 20 Sept 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 10 Sept 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Sept 2024 — NON-FINAL ACTION E-MAILED
- 10 Sept 2024 — NON-FINAL ACTION WRITTEN